Global Rare Biomarkers Specimen Collection and Stabilization Market, By Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles), Product (Isolation Kits and Reagents, Blood Collection Tubes, and Systems), Specimen (Serum/Plasma, Others), Nucleic Acid and Other Biomolecules (RNA, DNA, Others), Application (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Others), End Use (Hospitals, Perinatal Clinics, Public Health Labs, Private or Commercial Labs, Physician Labs, Research Institutes, Others)– Industry Trends and Forecast to 2029
Rare Biomarkers Specimen Collection and Stabilization Market Analysis and Size
The market size for rare biomarkers specimen collection and stabilization is anticipated to grow over the forecast period. The industry is being driven by a significant rise in the number of studies showing how circulating biomarkers are used to control disease. The market's revenue growth has been significantly impacted by factors including rising demand for personalised medicine and rising desire for non-invasive disease treatment.
Data Bridge Market Research analyses that the rare biomarkers specimen collection and stabilization market which was USD 28.69 billion in 2021, would rocket up to USD 57.59 billion by 2029, and is expected to undergo a CAGR of 9.1% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles), Product (Isolation Kits and Reagents, Blood Collection Tubes, and Systems), Specimen (Serum/Plasma, Others), Nucleic Acid and Other Biomolecules (RNA, DNA, Others), Application (NIPT, Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Others), End Use (Hospitals, Perinatal Clinics, Public Health Labs, Private or Commercial Labs, Physician Labs, Research Institutes, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), QIAGEN (Germany), PerkinElmer, Inc. (U.S.), Merck KGaA (Germany ), Bio-Rad Laboratories, Inc. (U.S.), Enzo Biochem, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Eurofins Scientific (Luxembourg), Agilent Technologies, Inc. (U.S.), Bruker (U.S.), Siemens (U.S.), Epigenomics AG (Germany), General Electric (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Biomarkers (also known as signature molecule or molecular marker) are basically utilized to check how the body responds to a treatment of any condition or disease and assist in examining the organ functions and other health conditions. These play a vital role in the imaging technology so that they can provide clear imaging of oncology tumors and other problems.
Rare Biomarkers Specimen Collection and Stabilization Market Dynamics
Drivers
- Increasing number of patients with rising population
The rising need for non-invasive cancer diagnostics is one of the major factors propelling the rare biomarkers specimen collection and stabilization market forward. Furthermore, the rising number of cancer patients and research programmes, as well as the rise in unhealthy lifestyles and chronic diseases like as diabetes and cardiovascular problems, all contribute to the market's overall growth.
- Increasing number of CROs
The low cost of clinical trials in emerging countries, the increasing prevalence of cancer, and new research initiatives are expected to accelerate the rare biomarkers market's growth during the forecast period. The use of minimally invasive techniques for the identification of conditions such as cancer, represents an opportunity that will start the development of the rare biomarkers specimen collection and stabilization market in the forecast period 2022 to 2029.
- Growing importance of companion diagnostics
The rare biomarkers specimen collection and stabilization market is expected to rise due to reasons such as rising cancer prevalence worldwide, increased finances and grants for biomarker research, and continual product improvements.
Opportunities
Governments are also promoting biomarker technologies across Europe, which are boosting financing for biomarker research. As a result, increased R&D activities will likely boost the rare biomarkers specimen collection and stabilization market forward in the coming years. Furthermore, the increasing use of biomarker technologies in drug development and genome mapping studies, as well as a growing inclination for tailored medications, are driving the rare biomarkers specimen collection and stabilization market.
Restraints/Challenges
However, obstacles such as high investment requirements, high treatment costs, and expensive capital expenditure on equipment are expected to stymie market expansion, as are technical challenges with sample collection and a lack of suitable reimbursement.
This rare biomarkers specimen collection and stabilization market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the rare biomarkers specimen collection and stabilization market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Rare Biomarkers Specimen Collection and Stabilization Market
The COVID-19 outbreak caused widespread disruption in nearly every industry. However, this is not the case in the biomarker industry, as biomarkers are critical in the development of chronic-care medicines, where the government and pharmaceutical firms will invest heavily, stifling market growth. Various studies have been undertaken, and biomarkers have been discovered to have an important role in diagnosing and treating COVID-19.
Recent Development
- In February 2022, Abbott Laboratories released Lingo, a consumer bio wearable that can track important body signals and help consumers better understand and improve their overall health. It could allow biohackers to use a continuous stream of data rather than periodic finger-prick tests, urine samples, and breath readings.
- In February 2022, OncoDNA, a genomic and prognostic business, released the OncoDEEP kit. The kit provides a complete workflow solution that allows laboratories with NGS capabilities to undertake thorough biomarker testing, perform advanced data analysis, and assist oncologists in providing the most effective and customised cancer treatments for their patients.
- In December 2020, Neoantigen Presentation Score (NEOPS), a neoantigen-based composite biomarker for cancer immunotherapy response, was introduced by Personalis, Inc. To more accurately forecast how a patient will respond to cancer therapy, NEOPS integrates research from Personalis' tumour neoantigen prediction tool SHERPA with immune evasion mechanisms. This should accelerate market expansion. ?
Global Rare Biomarkers Specimen Collection and Stabilization Market Scope
The rare biomarkers specimen collection and stabilization market is segmented on the basis of type, product, application, specimen, nucleic acid and other biomolecules, end use. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Circulating Cell Free DNA (ccfDNA)
- Circulating Tumor Cells (CTCs)
- Exosomes/Extracellular Vesicles
Product
- Isolation Kits and Reagents
- Blood Collection Tubes
- Systems
Specimen
- Serum/Plasma
- Others
Nucleic Acid and Other Biomolecules
- RNA
- DNA
- Others
Application
- NIPT
- Oncology
- Transcriptomics
- Pharmacogenomics
- Transplant Rejection
- Population Screening
- Cardiovascular Diseases
- Others
End Use
- Hospitals
- Perinatal Clinics
- Public Health Labs
- Private or Commercial Labs
- Physician Labs
- Research Institutes
- Others
Rare Biomarkers Specimen Collection and Stabilization Market Regional Analysis/Insights
The rare biomarkers specimen collection and stabilization market is analysed and market size insights and trends are provided by country, type, product, application, specimen, nucleic acid and other biomolecules, end use as referenced above.
The countries covered in the rare biomarkers specimen collection and stabilization market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the rare biomarkers specimen collection and stabilization market due to the presence of a wide client base coupled with substantial number of FDA approved products.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the ongoing conferences and seminars for raising awareness about the role of rare biomarkers in disease management, among the Asian population including patients.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The rare biomarkers specimen collection and stabilization market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for rare biomarkers specimen collection and stabilization market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the rare biomarkers specimen collection and stabilization market. The data is available for historic period 2010-2020.
Competitive Landscape and Rare Biomarkers Specimen Collection and Stabilization Market Share Analysis
The rare biomarkers specimen collection and stabilization market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to rare biomarkers specimen collection and stabilization market.
Some of the major players operating in the rare biomarkers specimen collection and stabilization market are:
- F. Hoffmann-La Roche Ltd. (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Abbott (U.S.)
- QIAGEN (Germany)
- PerkinElmer, Inc. (U.S.)
- Merck KGaA (Germany )
- Bio-Rad Laboratories, Inc. (U.S.)
- Enzo Biochem, Inc. (U.S.)
- Charles River Laboratories International, Inc. (U.S.)
- Eurofins Scientific (Luxembourg)
- Agilent Technologies, Inc. (U.S.)
- Bruker (U.S.), Siemens (U.S.)
- Epigenomics AG (Germany)
- General Electric (U.S.)
SKU-